Canesten
clotrimazole (topical)
(kloe-trye-ma-zole) clotrimazole,Canesten
(trade name),Clotrimaderm
(trade name),Cruex
(trade name),Lotrimin AF
(trade name)Classification
Therapeutic: antifungalsIndications
Action
Therapeutic effects
Pharmacokinetics
Time/action profile
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| Top | unknown | unknown | unknown |
Contraindications/Precautions
Adverse Reactions/Side Effects
Local
- burning
- itching
- local hypersensitivity reactions
- redness
- stinging
Interactions
Drug-Drug interaction
Not known.Route/Dosage
Availability (generic available)
Nursing implications
Nursing assessment
- Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.
Potential Nursing Diagnoses
Risk for impaired skin integrity (Indications)Risk for infection (Indications)
Implementation
- Consult health care professional for proper cleansing technique before applying medication.
- Topical: Apply small amount to cover affected area completely. Avoid the use of occlusive wrappings or dressings unless directed by health care professional.
Patient/Family Teaching
- Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Emphasize the importance of avoiding the eyes.
- Caution patient that some products may stain fabric, skin, or hair. Check label information. Fabrics stained from cream can usually be cleaned by handwashing with soap and warm water.
- Patients with athlete’s foot should be taught to wear well-fitting, ventilated shoes, to wash affected areas thoroughly, and to change shoes and socks at least once a day.
- Advise patient to report increased skin irritation or lack of response to therapy to health care professional.
- Inform patient that early relief of symptoms may be seen in 2–3 days. For Candida, tinea cruris, and tinea corporis, 2 wk are needed, and for tinea pedis, therapeutic response may take 3–4 wk. Recurrent fungal infections may be a sign of systemic illness.
Evaluation/Desired Outcomes
- Decrease in skin irritation and.
- Resolution of infection.
clotrimazole (vaginal)
(kloe-trye-ma-zole) clotrimazolevaginal,Canesten
(trade name),Clotrimaderm
(trade name),Gyne-Lotrimin-3
(trade name),Mycelex-7
(trade name)Classification
Therapeutic: antifungalsIndications
Action
Therapeutic effects
Pharmacokinetics
Time/action profile
| ROUTE | ONSET | PEAK | DURATION |
|---|---|---|---|
| cream | Unknown | 8–24 hr | Unknown |
| tablet | Unknown | 1–2 days | Unknown |
Contraindications/Precautions
Adverse Reactions/Side Effects
Genitourinary
- itching
- soreness
- vulvovaginal burning
Interactions
Drug-Drug interaction
Not known.Route/Dosage
Availability (generic available)
Nursing implications
Nursing assessment
- Inspect involved areas of skin and mucous membranes before and frequently during therapy. Increased skin irritation may indicate need to discontinue medication.
Potential Nursing Diagnoses
Risk for infection (Indications)Risk for impaired skin integrity (Indications)
Implementation
- Consult physician or other health care professional for proper cleansing technique before applying medication.
- Vaginal: Applicators are supplied for vaginal administration.
Patient/Family Teaching
- Instruct patient to apply medication as directed for full course of therapy, even if feeling better. Therapy should be continued during menstrual period.
- Advise patient to avoid using tampons while using this product.
- Instruct patient on proper use of vaginal applicator. Medication should be inserted high into the vagina at bedtime. Instruct patient to remain recumbent for at least 30 min after insertion. Advise use of sanitary napkins to prevent staining of clothing or bedding.
- Advise patient to consult health care professional regarding intercourse during therapy. Vaginal medication may cause minor skin irritation in sexual partner. Advise patient to refrain from sexual contact during therapy. Advise patient that this medication may weaken latex or rubber contraceptive products. Another method of contraception should be used during treatment.
- Advise patient to report to health care professional increased skin irritation or lack of response to therapy. A second course may be necessary if symptoms persist.
- Advise patient to dispose of applicator after each use.
- Advise patient that therapeutic response is usually seen after 1 wk. Before a second course of therapy is initiated, diagnosis should be reconfirmed with smears or cultures to rule out other pathogens associated with vulvovaginitis. Recurrent vaginal infections may be a sign of systemic illness.
Evaluation/Desired Outcomes
- Decrease in skin irritation and vaginal discomfort.
- Resolution of infection.